**International ALL Assembly**

**20–21 January 2017**

**Sana Lisboa Hotel, Lisbon, Portugal**

**Programme**

***Co-chairs:*** *Franco Locatelli, Italy; Hervé Dombret, France****20–21 January 2017***

|  |  |  |
| --- | --- | --- |
| **DAY 1** | | |
| **Time** | **Session** | Proposed speaker  [back-up]/**Chair** |
| 12.00–13.00 | **Lunch** |  |
| 13.00–13.05 | * Welcome and introduction | João Lacerda, Portugal; **Franco Locatelli, Italy** |
| 13.05–13.15 | * ALL in 2017: recent progress and ongoing challenges | Dieter Hoelzer (Germany) |
| ***Session 1*** | ***Updates in ALL treatment: are we progressing towards ‘personalised’ targeted approaches?*** | **Franco Locatelli (Italy)** |
| 13.15‒13.35 | * New genetic markers in ALL | Charles Mullighan (USA) |
| 13.35–13.55 | * Novel treatment approaches in Philadelphia-like ALL | Judith Boer (the Netherlands) |
| 13.55–14.15 | * Novel treatment approaches in early T-cell  precursor (ETP) ALL | Jan Cools (Belgium) |
| 14.15–14.35 | * New genetic subgroups in paediatric ALL | Giovanni Cazzaniga (Italy) |
| 14.35–14.50 | **Panel discussion** | All session 1 faculty |
| 14.50–15.20 | **Coffee break** |  |
| ***Session 2*** | ***Updates in ALL treatment: current status of antigen-targeted treatments and immunotherapy*** | **Nicola Gökbuget (Germany)** |
| 15.20–15.40 | * Antibodies and immunoconjugates | Giovanni Martinelli (Italy) |
| 15.40–16.00 | * T-cell-engaging therapies: bispecific T-cell engager (BiTE) and dual-affinity re-targeting (DART) antibody constructs | Max Topp (Germany) |
| 16.00–16.20 | * Chimeric antigen-receptor (CAR) T cells | Stephan Grupp (USA) |
| 16.20–16.40 | * Allogeneic natural killer cell therapies | Rupert Handgretinger (Germany) |
| 16.40‒16.55 | **Panel discussion** | All session 2 faculty |
| 16.55–18.00 | ***Special interest workshops*** |  |
| Workshops to run once only – each delegate to select preferred workshop | * Identification and management of toxicities associated with immunotherapy for ALL | Max Topp (Germany) |
| * Identification and management of veno-occlusive disease | Enric Carreras (Spain) |
| * Precision medicine in ALL | Ching-Hon Pui (USA) |
| * ALL diagnostics | Sabina Chiaretti (Italy) |
| * The management of CNS involvement in ALL | Sebastian Giebel (Poland) |
| **19.00** | **Dinner** |  |

|  |  |  |
| --- | --- | --- |
| **DAY 2** | | |
| **Time** | **Session** | Speaker/**chair** |
| 09.00–09.05 | **Welcome and introduction to Day 2** | **Hervé Dombret (France)** |
| ***Session 3*** | ***The evolution of approaches to monitor MRD in ALL*** | **Renato Bassan (Italy)** |
| 09.05–09.20 | * Standardised flow cytometry | Alberto Orfao (Spain) |
| 09.20–09.35 | * MRD monitoring by PCR | Michael Kneba  (Germany) |
| 09.35–09.50 | * Next-generation sequencing (NGS) | Monika Brüggemann (Germany) |
| 09.50–10.05 | **Panel discussion** | All session 3 faculty |
| ***Session 4*** | ***The evolution of transplant in ALL*** | **Josep Ribera (Spain)** |
| 10.05–10.20 | * Haplo or matched allogeneic stem cell transplant? | Fabio Ciceri (Italy) |
| 10.20–10.35 | * Transplant in the elderly ALL patient | Mohamad Mohty (France) |
| 10.35–10.50 | * The role of autologous transplant in ALL | Sebastian Giebel (Poland) |
| 10.50‒11.05 | **Panel discussion** | All session 4 faculty |
| 11.05–11.35 | **Coffee break** |  |
| 11.35–13.10 | **Interactive ‘Meet the expert/How I treat’ workshops** |  |
| 2 x 45 min + 5 min changeover  Workshops to run twice – each delegate to select 2 preferred workshops | * How I treat the elderly patients with ALL | Josep Ribera (Spain) |
| * How I treat paediatric ALL | Franco Locatelli (Italy) |
| * How I treat Philadelphia chromosome-positive (Ph+) ALL | Oliver Ottmann (UK) |
| * How I treat relapsed/refractory ALL | Nicola Gökbuget (Germany) |
| * How I treat T-ALL/lymphoblastic lymphoma | Renato Bassan (Italy) |
| * How I treat Burkitt’s lymphoma | Dieter Hoelzer (Germany) |
| * How I treat adolescents and young adults with ALL | Nicolas Boissel (France) |
| 13.10–14.10 | **Lunch** |  |
| ***Session 5*** |  | **Dieter Hoelzer (Germany)** |
| 14.10–15.10 | **Debate:** Debate: Do we still need to transplant high-risk  patients aged 18 and above who become MRD-negative after initial therapy? |  |
| 14.10–14.15: *Introduction and voting* | Dieter Hoelzer (Germany) |
| 14.15–14.35: *Yes* | David Marks (UK) |
| 14.35–14.55: *No* | Josep Ribera (Spain) |
| 14.55–15.05: *panel and delegates challenging speakers* | Moderated by Dieter Hoelzer |
| 15.05–15.10: *voting and close* | Dieter Hoelzer (Germany) |
| 15.10–15.25 | Future horizons in ALL: what could we expect next? | Hervé Dombret (France) |
| 15.25–15.40 | Panel discussion | All SC members |
| 15.40‒15.45 | Summary and close | Franco Locatelli (Italy)/  Hervé Dombret (France) |